Ascendis Pharma ASMEX:ASNDN 37 PEG Ratio is 0.00 as of Jun. 25, 2026. GuruFocus rates MEX:ASNDN with a GF Score™ of 37/100. The stock has 1 warning sign investors should review. Among 95 Biotechnology companies, Ascendis Pharma AS ranks better than 65.26% on this metric.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Ascendis Pharma AS's PEG Ratio or its related term are showing as below:
MEX:ASNDN'
s PEG Ratio Range Over the Past 10 Years
Min: 0.59 Med: 0.65 Max: 1.1
Current: 1.1
During the past 13 years, Ascendis Pharma AS's highest PEG Ratio was 1.10. The lowest was 0.59. And the median was 0.65.
MEX:ASNDN's PEG Ratio is ranked better than 65.26% of 95
companies
in the Biotechnology industry
Industry Median: 1.93
vs MEX:ASNDN: 1.10
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Ascendis Pharma AS (MEX:ASNDN) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Ascendis Pharma AS PEG Ratio Related Terms
Ascendis Pharma AS PEG Ratio Historical Data
* Premium members only.
The historical data trend for Ascendis Pharma AS's PEG Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:ASNDN vs SMMT, BBIO, JAZZ: PEG Ratio Comparison
For the Biotechnology subindustry, Ascendis Pharma AS's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ascendis Pharma AS PEG Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ascendis Pharma AS's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Ascendis Pharma AS's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Ascendis Pharma AS (MEX:ASNDN) has a PEG Ratio of 0.00 as of Jun. 25, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Ascendis Pharma AS and its competitors. Over the past decade, Ascendis Pharma AS's PEG Ratio has ranged from 0.59 to 1.10. According to the industry distribution chart, Ascendis Pharma AS ranks #33 out of 95 companies in the Biotechnology industry, placing it in the top 34.7%.
Is Ascendis Pharma AS's PEG Ratio too high?
Ascendis Pharma AS's current PEG Ratio is 0.00. Over the past 10 years, this metric has ranged from a low of 0.59 to a high of 1.10. Based on the distribution chart, Ascendis Pharma AS ranks #33 out of 95 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Ascendis Pharma AS has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Ascendis Pharma AS's PEG Ratio compare to SMMT and BBIO?
According to the Biotechnology industry distribution chart, Ascendis Pharma AS ranks #33 out of 95 companies for PEG Ratio. This puts Ascendis Pharma AS in the upper half of its industry. The industry median PEG Ratio is 1.93. Historically, Ascendis Pharma AS's own PEG Ratio has ranged from 0.59 to 1.10 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Biotechnology company?
The median PEG Ratio among Biotechnology companies is 1.93, based on 95 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Ascendis Pharma AS and its competitors. For the Biotechnology industry, the median PEG Ratio is 1.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ascendis Pharma AS's current PEG Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascendis Pharma AS stock overvalued right now?
Ascendis Pharma AS (MEX:ASNDN) has a current PEG Ratio of 0.00. The current PEG Ratio is 0.00. Ascendis Pharma AS's overall GF Score™ is 37/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Ascendis Pharma AS (MEX:ASNDN), the current PEG Ratio is 0.00 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.
37GF Score
Get the complete analysis for MEX:ASNDN
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:ASNDN has been successfully added to your 
